These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17906679)

  • 21. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
    Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
    Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protocol for crystal structure determination of the antagonist-bound human cannabinoid receptor CB2.
    Shen L; Li X; Liu J; Liu K; Liu ZJ; Hua T
    STAR Protoc; 2021 Jun; 2(2):100584. PubMed ID: 34151302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.
    Marx IE; DiMauro EF; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Human J; Lee JH; Li X; Martin MW; White RD; Fremeau RT; Patel VF
    Bioorg Med Chem Lett; 2009 Jan; 19(1):31-5. PubMed ID: 19062274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists.
    Aghazadeh Tabrizi M; Baraldi PG; Ruggiero E; Saponaro G; Baraldi S; Poli G; Tuccinardi T; Ravani A; Vincenzi F; Borea PA; Varani K
    Eur J Med Chem; 2016 May; 113():11-27. PubMed ID: 26922225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.
    Gómez-Cañas M; Morales P; García-Toscano L; Navarrete C; Muñoz E; Jagerovic N; Fernández-Ruiz J; García-Arencibia M; Pazos MR
    Pharmacol Res; 2016 Aug; 110():205-215. PubMed ID: 27013280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CB2 receptor-mediated migration of immune cells: it can go either way.
    Miller AM; Stella N
    Br J Pharmacol; 2008 Jan; 153(2):299-308. PubMed ID: 17982478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
    Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
    Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism.
    Bettiga A; Aureli M; Colciago G; Murdica V; Moschini M; Lucianò R; Canals D; Hannun Y; Hedlund P; Lavorgna G; Colombo R; Bassi R; Samarani M; Montorsi F; Salonia A; Benigni F
    Sci Rep; 2017 Feb; 7():42157. PubMed ID: 28191815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and biochemical analyses of selective CB
    Scott CE; Tang Y; Alt A; Burford NT; Gerritz SW; Ogawa LM; Zhang L; Kendall DA
    Eur J Pharmacol; 2019 Jul; 854():1-8. PubMed ID: 30951717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular biology of cannabinoid receptors.
    Abood ME
    Handb Exp Pharmacol; 2005; (168):81-115. PubMed ID: 16596772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New QSAR prediction models derived from GPCR CB2-antagonistic triaryl bis-sulfone analogues by a combined molecular morphological and pharmacophoric approach.
    Chen JZ; Myint KZ; Xie XQ
    SAR QSAR Environ Res; 2011; 22(5-6):525-44. PubMed ID: 21714749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
    Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
    J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists.
    van der Stelt M; Cals J; Broeders-Josten S; Cottney J; van der Doelen AA; Hermkens M; de Kimpe V; King A; Klomp J; Oosterom J; Pols-de Rooij I; de Roos J; van Tilborg M; Boyce S; Baker J
    J Med Chem; 2011 Oct; 54(20):7350-62. PubMed ID: 21923175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.
    Dhopeshwarkar A; Murataeva N; Makriyannis A; Straiker A; Mackie K
    J Pharmacol Exp Ther; 2017 Feb; 360(2):300-311. PubMed ID: 27927913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabichromene is a cannabinoid CB
    Udoh M; Santiago M; Devenish S; McGregor IS; Connor M
    Br J Pharmacol; 2019 Dec; 176(23):4537-4547. PubMed ID: 31368508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.
    Feng R; Tong Q; Xie Z; Cheng H; Wang L; Lentzsch S; Roodman GD; Xie XQ
    Mol Carcinog; 2015 Dec; 54(12):1796-806. PubMed ID: 25640641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor.
    Taylor L; Christou I; Kapellos TS; Buchan A; Brodermann MH; Gianella-Borradori M; Russell A; Iqbal AJ; Greaves DR
    Sci Rep; 2015 Jun; 5():10682. PubMed ID: 26033291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.
    Basu S; Dittel BN
    Immunol Res; 2011 Oct; 51(1):26-38. PubMed ID: 21626285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.
    Deiana V; Gómez-Cañas M; Pazos MR; Fernández-Ruiz J; Asproni B; Cichero E; Fossa P; Muñoz E; Deligia F; Murineddu G; García-Arencibia M; Pinna GA
    Eur J Med Chem; 2016 Apr; 112():66-80. PubMed ID: 26890113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses.
    Bouaboula M; Dussossoy D; Casellas P
    J Biol Chem; 1999 Jul; 274(29):20397-405. PubMed ID: 10400664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.